Antithrombin Alfa (ATryn®) Therapy in Hereditary Antithrombin (AT) Deficient Patients:  A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations

[No Value] Tiede A; J, Tait RC, Shaffer D, Baudo F, Boneu B, Dempfle C, Horellou M, Klamroth R, Lazarchick; AD Mumford; [No Value] Schulman S, Bonfiglio J, Frieling  J, Conard J, von Depka M.

Antithrombin Alfa (ATryn®) Therapy in Hereditary Antithrombin (AT) Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations

[No Value] Tiede A, J, Tait RC, Shaffer D, Baudo F, Boneu B, Dempfle C, Horellou M, Klamroth R, Lazarchick, AD Mumford, [No Value] Schulman S, Bonfiglio J, Frieling J, Conard J, von Depka M.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

Translated title of the contribution	Antithrombin Alfa (ATryn®) Therapy in Hereditary Antithrombin (AT) Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations
Original language	English
Pages (from-to)	616 - 612
Journal	Thrombosis and Haemostasis
Volume	99
Publication status	Published - 2008

Handle.net

Persistent link

Cite this

Tiede A, N. V., Tait RC, Shaffer D, Baudo F, Boneu B, Dempfle C, Horellou M, Klamroth R, Lazarchick, J., Mumford, AD., & Schulman S, Bonfiglio J, Frieling J, Conard J, von Depka M., N. V. (2008). Antithrombin Alfa (ATryn®) Therapy in Hereditary Antithrombin (AT) Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations. Thrombosis and Haemostasis, 99, 616 - 612.

@article{8f4c366f25e14075aea603c111ec630a,

title = "Antithrombin Alfa (ATryn{\textregistered}) Therapy in Hereditary Antithrombin (AT) Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations",

author = "{Tiede A}, {[No Value]} and {Tait RC, Shaffer D, Baudo F, Boneu B, Dempfle C, Horellou M, Klamroth R, Lazarchick}, J, and AD Mumford and {Schulman S, Bonfiglio J, Frieling J, Conard J, von Depka M.}, {[No Value]}",

year = "2008",

language = "English",

volume = "99",

pages = "616 -- 612",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

publisher = "Schattauer GmbH",

}

Tiede A, NV, Tait RC, Shaffer D, Baudo F, Boneu B, Dempfle C, Horellou M, Klamroth R, Lazarchick, J, Mumford, AD & Schulman S, Bonfiglio J, Frieling J, Conard J, von Depka M., NV 2008, 'Antithrombin Alfa (ATryn®) Therapy in Hereditary Antithrombin (AT) Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations', Thrombosis and Haemostasis, vol. 99, pp. 616 - 612.

Antithrombin Alfa (ATryn®) Therapy in Hereditary Antithrombin (AT) Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations. / Tiede A, [No Value]; Tait RC, Shaffer D, Baudo F, Boneu B, Dempfle C, Horellou M, Klamroth R, Lazarchick, J,; Mumford, AD et al.

In: Thrombosis and Haemostasis, Vol. 99, 2008, p. 616 - 612.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - Antithrombin Alfa (ATryn®) Therapy in Hereditary Antithrombin (AT) Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations

AU - Tiede A, [No Value]

AU - Tait RC, Shaffer D, Baudo F, Boneu B, Dempfle C, Horellou M, Klamroth R, Lazarchick, J,

AU - Mumford, AD

AU - Schulman S, Bonfiglio J, Frieling J, Conard J, von Depka M., [No Value]

PY - 2008

Y1 - 2008

M3 - Article (Academic Journal)

VL - 99

SP - 616

EP - 612

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

ER -

Tiede A NV, Tait RC, Shaffer D, Baudo F, Boneu B, Dempfle C, Horellou M, Klamroth R, Lazarchick J, Mumford AD, Schulman S, Bonfiglio J, Frieling J, Conard J, von Depka M. NV. Antithrombin Alfa (ATryn®) Therapy in Hereditary Antithrombin (AT) Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations. Thrombosis and Haemostasis. 2008;99:616 - 612.